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Conformational altered p53 affects neuronal function:
relevance for the response to toxic insult and
growth-associated protein 43 expression
L Buizza*,1, C Prandelli1, SA Bonini1, A Delbarba2, G Cenini1, C Lanni3, E Buoso3, M Racchi3, S Govoni3, M Memo1 and D Uberti1
The role of p53 in neurodegenerative diseases is essentially associated with neuronal death. Recently an alternative point of view
is emerging, as altered p53 conformation and impaired protein function have been found in fibroblasts and blood cells derived
from Alzheimer’s disease patients. Here, using stable transfected SH-SY5Y cells overexpressing APP751wt (SY5Y-APP) we
demonstrated that the expression of an unfolded p53 conformation compromised neuronal functionality. In particular, these cells
showed (i) augmented expression of amyloid precursor protein (APP) and its metabolites, including the C-terminal fragments
C99 and C83 and b-amyloid peptide (ii) high levels of oxidative markers, such as 4-hydroxy-2-nonenal Michael-adducts and
3-nitro-tyrosine and (iii) altered p53 conformation, mainly due to nitration of its tyrosine residues. The consequences of high-
unfolded p53 expression resulted in loss of p53 pro-apoptotic activity, and reduction of growth-associated protein 43 (GAP-43)
mRNA and protein levels. The role of unfolded p53 in cell death resistance and lack of GAP-43 transcription was demonstrated by
ZnCl2 treatment. Zinc supplementation reverted p53 wild-type tertiary structure, increased cells sensitivity to acute cytotoxic
injury and GAP-43 levels in SY5Y-APP clone.
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Introduction
p53 is a pleiotropic protein involved in a very large number of
biological processes, including cell cycle regulation, cell
differentiation and apoptosis.1 Regulation of p53 activity is
crucial in determining cellular outcome: p53 promotes DNA
repair or induces apoptosis upon cytotoxic insults.2 The cell
fate depends on the damage degree and on the cellular
phenotype.3
In central nervous system, p53 signaling has been often
associated with neuronal death.4–6 While, during brain
development, p53 is required to eliminate neuron excess
in order to ensure the correct neuronal cytoarchitecture,7 in
mature neurons p53-mediated cell death is correlated
with neurodegeneration.8 Indeed, several data demonstrated
that different excitotoxic insults induced apoptosis in a p53-
dependent manner, leading to progressive decline of neuronal
functionality and finally cellular death.9–11 Furthermore,
increased p53 immunoreactivity associated with neuronal
death was observed in models of cerebral ischemia, traumatic
brain injury and epilepsy.8,12 In agreement with these data,
many studies demonstrated that inhibition of p53 prevented
cell death in a variety of neurodegenerative models.13,14
Interestingly, an intriguing non-apoptotic role for p53 has
been proposed by recent research carried out by Di Giovanni
and co-workers.15 Surprisingly, p53 is required for axonal
outgrowth in primary neurons, as well as for axonal
regeneration following neuronal injury in mice, probably
through different post-translational pathways. Loss of p53
activity, induced by specific p53 inhibitors or by transfection
with dominant-negative forms of p53, compromises synaptic
remodeling, leading to neuronal dysfunction.16 p53 transacti-
vates neuronal growth-associated protein 43 (GAP-43), a
protein involved in neuronal morphology.17 This protein is the
major constituent of the growth-cone and has a key role in
guiding the growth of axons and modulating the formation of
new connections.18 Downregulation of GAP-43 expression
may reflect an important molecular lesion that precedes
and progresses with widespread synaptic disconnections and
neurodegeneration.19
Hence, the role of p53 in neurodegenerative diseases could
be revised, because an impairment, rather than an excessive
activation, of p53 intracellular signaling may be involved in the
development of neuronal dysfunction. Our group demon-
strated that conformational changes in p53 tertiary structure
was present in peripheral cells (that is, fibroblasts and blood
cells) derived from Alzheimer’s (AD) patients.20–22 In addition,
Serrano et al.,23 showed that old AD transgenic mice
APPswe/PS1-A246E exhibited a mutated p53 conformation
and were more prone to develop brain tumor after carcinogen
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20-methycholanthrene injection, compared with younger
mutants and with wild-type counterparts of the same age.
AD is a slowly progressing disorder characterized
by memory loss and cognitive decline.24
Abnormal production and deposition of Ab peptides in the
brain is one of the most reliable causes of AD pathogenesis.25
Ab derives from amyloidogenic processing of a protein named
amyloid precursor protein (APP), whose gene mutations are
correlated with familiar cases of AD.26 In addition, reduced
GAP-43 expression was observed in AD brain,27–29 suggest-
ing a synaptic disfunction in the development of the disease.
Thus, this study investigated the contribution of p53
conformational changes to neuronal dysfunction and neuronal
death in AD, using a human neuroblastoma cell line SH-SY5Y
steadily transfected with APP751-wild-type (called SY5Y-
APP). We demonstrated that SY5Y-APP cells showed an
impairment in neuronal responses against acute toxic insults
and a reduction of GAP-43 levels, due to a lack of p53
trascriptional activity.
Results
Characterization of SY5Y-APP clone. SY5Y-APP cells
expressed increased APP mRNA (Figure 1a), and protein
levels (Figure 1b) as measured by real-time PCR (RT-PCR)
and western blot analysis with 22C11 antibody (that
recognized N-terminus of APP), respectively. In addition,
we demonstrated an enhanced APP metabolism in SY5Y-
APP clone if compared with mock cells. Western blot
analysis performed with 6E10 antibody (recognizing the
fragment 1–17 of Ab) revealed exclusively in SY5Y-APP
clone the presence of different bands corresponding to
different APP metabolic products: APP full-length of about
150 kDa; a band at 100 kDa corresponding to immature
protein, one at 50 kDa, reported in litterature as a metabolic
product of amyloidogenic pathway;30 and finally smear bands
around 15-8 kDa corresponding to C-terminus fragments
(bCTFs). Immunostaining with APP-C-terminus antibody
identified two bands corresponding to C99 and C83
fragments that were significantly more intensive in SY5Y-
APP clone in comparison with mock cells. Figure 1c showed
confocal microscopy analysis with a specific antibody against
Ab peptide. Cells overexpressing APP showed an evident
accumulation of b-amyloid staining.
SY5Y-APP cells showed a high oxidative stress and
conformational altered p53 expression. Recent data point
an intriguing relationship between Ab and oxidative stress.31
Oxidative stress was evaluated by measuring the expres-
sion of different oxidative markers; especially, we focused on
protein-bound 4-hydroxy-2-nonenal (HNE), a product of lipid
peroxidation,32 and 3-nitrotyrosine (3NT), which, via perox-
ynitrite, results in the addition of a nitro-group to tyrosine
residues.33 HNE and 3NT products were found significantly
enhanced in SY5Y-APP clone in relation with mock cells
(Figures 2a and b), suggesting the presence of an increased
oxidative environment in this clone.
It is well recognized that p53 is particularly sensitive to
cellular redox modulation.34 At this regards, we recently
demonstrated a correlation between oxidative stress and
nitrated-p53 in blood peripheral cells derived from sporadic
and familiar AD patients.35 Nitration of p53-tyrosine residues
was demonstrated to change its tertiary structure in an
unfolded conformation.35 In this study, SY5Y-APP and mock
cells were immunoprecipitated with two conformationally
specific antibodies (PAb1620 antibody, direct towards
Figure 1 Characterization of SY5Y-APP clone. mRNA and protein extracts were obtained from Mock cells and SY5Y-APP clone. (a) Q-RT-PCR was performed using
RNA extracted from mock and SY5Y-APP cells to evaluate APP expression levels. Data were expressed as fold change of target gene expression, normalized to the
internal control gene (GAPDH). Data were analyzed according to the comparative Ct method. (b) Western blot analysis was carried out with different anti-APP antibodies
(22C11 against N-terminal amino acids; 6E10 against fragment 1–17 of Ab and C-terminus against the last C-terminus nine amino acids). Anti-nucleolin antibody was used to
normalize protein content. (c) Confocal microscopy analysis was performed using an anti-Ab peptide on mock and SY5Y-APP cells
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wild-type form of the protein, competent for DNA binding and
PAb240, which recognizes an epitope cryptic when the protein
is in its folded form and accessible when the protein
undergoes conformational changes36), and then blotted with
a polyclonal anti-p53 antibody. Cells transfected with empty
vector expressed mainly wild-type p53, as demonstrated by
the reactivity with PAb1620 and the poor responsiveness to
PAb240. SY5Y-APP cells showed a band reactive to PAb240
antibody in association with PAb1620-positive band
(Figure 2c). Immunoprecipitated extracts were also immuno-
blotted with anti-HNE or anti-3NT antibodies to investigate
the degree of oxidation/nitration of p53 molecule in the two
conformations. As shown in Figure 2c, HNE-p53 band was
evident especially in the SY5Y-APP sample immunoprecipi-
tated with PAb1620 (wt conformation). Differently, a weak
3NT-p53-positive band was observed in mock extracts
immunoprecipitated with PAb240 antibody (unfolded p53),
whereas in SY5Y-APP cells, nitration of tyrosine residues was
more evident in both wild-type (PAb1620) and unfolded
(PAb240) conformations. Quantitative analysis of 3NT/HNE-
p53-positive bands were done on three different immunoblots
derived from three different cell preparations. Data were
expressed as the ratio between 3NT/HNE-p53 intensity band
on the corresponding p53 conformational isoforms. As
reported in Figure 2d, 3NT-unfolded and 3NT-wild-type p53
levels were statistically increased in SY5Y-APP clone in
comparison with mock cells. At variance, SY5Y-APP clone
showed high HNE-p53 expression, especially when the
protein was in its native conformation.
SY5Y-APP cells resulted less sensitive to acute toxic
stress. To investigate the consequence of unfolded
p53 expression on cellular responses upon a toxic insult,
SY5Y-APP and mock cells were exposed to a brief pulse of
H2O2 (see methods section). H2O2 induced a reduction of
cell viability of about 50% in mock cells, whereas SY5Y-APP
cells resulted more resistant to the oxidative insult
(Figure 3a). As expected, in mock cells oxidative injury
induced p53 pathway activation within few hours: p53 protein
expression increased already at 1 h after the H2O2 stimulus
and remained high at least until 4 h; p21 protein levels, a
target gene of p53, significantly increased at 4h following
insult. In SY5Y-APP cells, p53 intracellular pathway was
impaired. We found the lack of an increased p53 expression
(that was anyway already high in basal condition) and p21
expression (Figure 3b). p53 transcriptional activity was also
evaluated by transfecting cells with p53AIP1-luciferase
apoptotic promoter. As shown in Figure 3c, p53AIP1-
luciferase activity was induced by doxorubicin treatment in
mock cells. At variance, in SY5Y-APP clone p53 activity
induced by noxious insult was significantly impaired. Notably,
H2O2 and doxorubicin injuries did not affect p53 unfolded
conformation in mock and SY5Y-APP cells, while these toxic
insults induced, as expected, the increased expression of
p53 wild-type only in mock cells (data not shown).
SY5Y-APP cells showed GAP-43 dependent impairment
in axonal outgrowth. Accumulating evidence suggested a
role of p53 in neuronal maturation and axonal outgrowth,
Figure 2 Elevated oxidative markers in SY5Y-APP cells. (a and b) Mock cells and SY5Y-APP clone were processed for measurement of oxidative markers by Dot blot
analysis using specific antibodies against protein-bound-HNE and 3NT. a-tubulin expression was used to normalize protein content. Data are represented as mean±S.E.M.
of at least three different experiments. *Po0.05 MOCK versus SY5Y-APP; **Po0.001 MOCK versus SY5Y-APP. (c) Immunoprecipitated experiments with two
conformational specific anti-p53 antibodies that recognized wild-type (PAb1620) and unfolded (PAb240) p53 state. Immunoprecipitated p53 was then loaded on 10% SDS-
PAGE gel and immunoblotted with anti-p53; anti-HNE and anti-3NT antibodies. (d) Quantitative analysis of 3NT/HNE-p53 positive bands were done on three different
immunoblots derived from three different cell preparations. Data were expressed as the ratio between oxidated/nitrated-p53 intensity band on the corresponding p53
conformational isoforms
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transactivating GAP-43 gene.15,37,38 Hence, we wonder
whether in SY5Y-APP cells, that expressed unfolded p53,
the expression of GAP-43 was compromised. For this
purpose, SY5Y-APP and mock cells were evaluated in term
of GAP-43 mRNA and protein levels. RT-PCR demonstrated
a fivefold reduction of GAP-43 mRNA in SY5Y-APP clone in
comparison with mock cells (Figure 4a). In addition western
blot analysis reflected the RT-PCR results, showing a
significant decrease of GAP-43 protein levels if compared
with mock cells (Figure 4b). Interestingly the expression of
b-III tubulin, a component of neuronal cytoskeleton, was
comparable in the SY5Y-APP and mock cells (Figure 4b).
The relevance of a GAP-43 downregulation in SY5Y-APP
clone was shown by the treatment with retinoic acid (RA). In
particular, mock cells and SY5Y-APP were exposed to RA for
48 h. RA exposure slightly increased GAP-43 expression in
SY5Y-APP cells (Figure 4c). However, this increase was not
correlated with p53 transcriptional activity, as it was not
prevented by 200 nM pifithrin-a (Pif), a specific p53 inhibitor.
The efficacy of pif-treatment was confirmed by the reduction
in mock cells of GAP-43 expression, whose gene is a target
gene of p53.15
Figure 4d showed representative confocal images that
evidence neurite elongation and growth-cone formation in
mock cells after 48 h RA exposure. As expected, growth-
cone area was GAP-43-positive in these cells. At variance
SY5Y-APP showed RA-induced neurite outgrowth, but a poor
growth-cone expansion with a weak GAP-43 staining
(Figure 4d). Retinoic-acid treatment had no effects on
both wild-type and unfolded p53 in SY5Y-APP cells.
Mock cells responded to RA treatment with an increased
expression of p53 wild-type isoform (data not shown).
This latter result was in line with different studies that
demonstrated a high expression of p53 after RA treatment,
suggesting its role in neurite outgrowth and neuronal
differentiation.39,40
SY5Y-APP phenotype was restore by zinc chloride
supplementation. p53 tertiary structure is endowed
with high flexibility.36 Different compounds influence p53
conformational state that shifts from wild-type to unfolded
phenotype and vice versa.36 For example, zinc chloride
restores p53 wild-type conformation, stabilizing the core
domain.41 At this regards, we exposed SY5Y-APP and mock
cells to zinc supplementation at the concentration of 100 mM
for 24 h and p53 conformational state was evaluated by
enzyme-linked Immunosorbent assay (ELISA) with PAb1620
and PAb240 antibodies.
The expression of unfolded p53 (PAb240 positive) was
significantly higher in SY5Y-APP clone than levels found in
mock cells (Figure 5a). The treatment with zinc chloride
mainly reduced the levels of PAb240 positive-p53 in SY5Y-
APP cells (Figure 5a). This effect was evident also in mock
cells showing a statistically significant reduction of unfolded
quote after zinc supplementation (Figure 5a). However, a
decrease of total p53 protein expression was observed
after zinc treatment in both SY5Y-APP and mock cells (data
not shown).
Zinc chloride also decreased the expression of PAb1620-
positive p53 in cells overexpressing APP (Figure 5b). In fact, a
huge amount of wild-type p53 was expressed in SY5Y-APP
cells if compared with mock cells. This result is consistent with
immunoprecipitation results reported in Figure 2c, and with
confocal analysis performed with PAb1620 and PAb240
antibodies (data not shown).
To test cell viability upon oxidative insult, the experiments
foresaw 24 h zinc pre-treatment in the absence or presence of
the p53 inhibitor Pif, followed by the acute oxidative insult. As
depicted in Figure 5c, mock cells showed a decrease of
B40% in cells survival, after H2O2 insult. The same result was
obtained in mock cells treated with zinc-chloride. Finally, pif-
treatment, alone or in association with zinc supplementation,
worked properly, precluding cell death. On the contrary,
SY5Y-APP cells showed a 20% decrease in cell survival after
H2O2 pulse. Zinc pre-treatment rendered this clone more
vulnerable to oxidative injury with a death estimated ofB50%.
When zinc pre-treatment was combined with pif pre-expo-
sure, H2O2-induced cell death was prevented in SY5Y-APP
cells (Figure 5d), suggesting that zinc rescued wild-type p53
conformation and pro-apoptotic activity.
Zinc supplementation also caused a 50% increase in
GAP-43 mRNA levels in SY5Y-APP clone, but not in mock
cells (Figure 6a). Furthermore, confocal microscopy
analysis, confirmed the increased protein expression of
GAP-43 induced by zinc supplementation in SY5Y-APP cells
(Figure 6b).
Figure 3 SY5Y-APP cells were less sensitive to toxic insults. Cells were
exposed to H2O2 pulse (5 min), followed by incubation with fresh medium for
different times (1, 4 and 24 h). (a) Cell viability was evaluated 24 h after oxidative
insults by MTT assay. Data were expressed as % of cell survival versus respective
controls. Values are the mean±S.E.M. of three different experiments. *Po0.001
H2O2- treated mock versus control mock. (b) Protein extracts derived from mock
and SY5-APP cells at 1 and 4 h after H2O2 pulse were processed for western blot
analysis with anti-p53, anti-p21 antibodies. Nucleolin was used for sample
normalization. (c) Mock and SY5Y-APP cells were transfected with p53AIP1-luc
promoter and 18 h later they were treated with 50 mM doxorubicin (Doxo). As much
as 24 h after toxic insult, cells were processed for the measurement of luciferase
activity. Data were expressed as % of relative luminescence unit (RLU)
***Po0.0001 Doxo-treated mock versus control mock
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To investigate the affinity of wild-type p53 protein for the
GAP-43 promoter elements, chromatin immunoprecipitation
assay (ChIP) was performed, after treating SY5Y-APP cells
with ZnCl2 in the presence or absence of RA. As shown in
Figure 6c, in basal condition p53 was mostly in unfolded
conformation and did not occupy GAP-43 promoter region.
Differently, treatment with ZnCl2 restored wild-type p53 that in
this conformation was found to occupy the GAP-43 promoter.
Retinoic-acid exposure did not substantially influenced the
effect of zinc chloride.
Moreover, when SY5Y-APP cells were differentiated by RA
in the presence of zinc-chloride, extensive growth cone area
GAP-43 positive was observed. Whereas in the absence of
zinc supplementation, RA induced in this clone only neurite
elongation, indicative of incomplete differentiation (Figure 7).
Discussion
In this study, we developed a clone of human neuroblastoma
cell line SH-SY5Y overexpressing APP751wt. This clone
appeared suitable to investigate molecular mechanisms
involved in AD. Indeed, if related to mock cells, SY5Y-APP
clone showed (i) elevated APP mRNA and protein levels, (ii)
increased expression of APP metabolites, among them CTFs
C99 and C83 and (iii) enhanced Ab peptide immunoreactivity.
Although ‘Ab cascade theory’ is one of the most accredited
hypothesis to explain the development of AD,42 a growing
body of evidence support a role of oxidative stress, as well
as inflammation mechanisms in the pathogenesis of the
disease.43–45 It is anyway debated whatever increased
oxidative stress could be a cause of Ab load or vice versa
Ab itself may be a pro-oxidant agent.46
SY5Y-APP clone showed a high oxidative environment
underlined by peculiar products of lipoperoxidation, such as
HNE Michael-adducts and peroxynitrite addition to tyrosine
residues, resulting in 3-nitro-tyrosine. This elevated oxidative
environment affected also p53 structure. In SY5Y-APP clone,
p53 is mainly present in unfolded conformation, as showed by
using two-specific conformational antibodies that discriminate
folded (PAb1620) versus unfolded (PAb240) p53 state. The
contribution of amyloidogenic metabolic products affecting
p53 conformational change towards an unfolded phenotype
was also supported by treating mock cells with nM concentra-
tion of Ab (Supplementary Figure 1A). In addition,
Ab pre-treatment at different concentration ranging from
0.02 to 10 nM protected the cells against oxidative insult
Figure 4 GAP-43 expression was decreased in SY5Y-APP cells. (a) Q-RT-PCR was performed using RNA extracted from mock and SY5Y-APP cells to evaluate GAP43
expression levels. Data were expressed as fold change of target expression, normalized to the internal control gene (GAPDH). Data were analyzed according to the
comparative Ct method. (b) Protein extracts derived from mock and SY5Y-APP cells were processed for western blot analysis carried out with anti-GAP-43 and anti-bIII
Tubulin antibodies. Nucleolin was used for sample normalization. (c) Mock and SY5Y-APP cells were exposed to RA in the presence or absence of Pif. Forty-eight hours later
cells were processed for western blot analysis using anti-GAP-43 antibody. Nucleolin was for sample normalization; pif-treatment efficacy was confirmed in mock cells by the
reduction of GAP-43 expression, whose gene is a target gene of p53. (d) Confocal microscopy analysis with anti-GAP43 and anti-b III tubulin antibodies was performed on
48 h RA-treated cells
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(Supplementary Figure 1B). This results were in line with our
previous data on human fibroblasts and HEK cells.47–49
This unfolded structure in SY5Y-APP cells was, at least in
part, the results of nitration to tyrosine residues of p53
molecule. Tyrosine-residues nitration was evident in both
wild-type and unfolded p53 conformation. This is plausible as
the p53 molecule contains 15 tyrosine residues, and 11 of
them are inside the highly flexible DNA-binding domain.50
Figure 5 ZnCl2 restored p53 wild-type conformation and SY5Y-APP cell sensitivity against oxidative insult. Cells were treated with 100mM ZnCl2 for 24 h and then
processed for p53 conformational analysis and cell viability. (a and b) ELISA immunoassay carried out with PAb240 (unfolded p53) (a) and PAb1620 (wild type p53) (b)
antibodies. (c and d) After 24 h ZnCl2 pretreatment, mock (c) and SY5Y-APP (d) cells were exposed to H2O2 pulse (5 min) in the presence or absence of the p53 inhibitor, Pif,
followed by incubation with fresh medium for additional 24 h. Cell viability was evaluated by MTT assay. Data were expressed as % of cell survival versus respective controls.
Values were the mean±S.E.M. of three different experiments. *Po0.001 ZnCl2 followed by H2O2-treated SY5Y-APP cells versus ZnCl2 pre-treated SY5Y-APP cells
Figure 6 ZnCl2 restored p53 transcriptional activity and GAP-43 expression. (a) Mock and SY5Y-APP cells were treated with 100mM ZnCl2 for 24 h and then cells were
processed for Q-RT-PCR. Data were expressed as fold change of GAP43 expression, normalized to the internal control gene (GAPDH). Data were analyzed according to the
comparative Ct method. (b) Mock and SY5Y-APP cells were treated with 100mM ZnCl2 for 24 h and then cells were processed for confocal microscopy analysis. Cells were
fixed in methanol, immunostained with anti-bIII tubulin and anti-GAP-43 antibodies, and analyzed to confocal microscopy. (c) SY5Y-APP cells untreated and treated with
ZnCl2 in the presence or absence of RA were processed for ChIP analysis. Cells were crosslinked with formaldehyde and immunoprecipitated with the polyclonal anti-p53 full
length antibody (FL-393). PCR analyses were performed on the immunoprecipitated DNA samples using specific primers for the GAP-43 promoter. A sample representing
linear amplification of the total input chromatin (Input) was included as control. Additional controls included immunoprecipitation performed with nonspecific immunoglobulins
(no Ab). Amplification of GADPH housekeeping gene was used as control of p53-binding specificity to the GAP43 promoter
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Probably, upon a certain degree of nitration or depending by
selective nitrated tyrosines, p53 shifted from wild-type
towards unfolded conformation. Similar results were found
in immortalized lymphocytes derived from familiar and
sporadic AD, as well as in cells derived from healthy donor
treated with peroxynitrite-generating compound SIN-1.35
According with our data, Calmels et al.51 demonstrated that
synthetic nitric oxide donors induce a conformational switch of
wild-type p53 to the unfolded form, with loss of DNA-binding
activity in vitro.
What is the relevance of unfolded p53 in neuron-like cells?
Firstly, our data showed that SY5Y-APP cells, as well as
mock cells treated with Ab, resulted more resistant to toxic
insults in comparison with mock cells. In particular, upon toxic
insults, mock cells responded by activating p53 intracellular
signaling that lead to the transactivation of pro-apoptotic
gene. On the contrary, in SY5Y-APP cells the lack of p53 pro-
apoptotic properties was the result of the presence of high
expression of unfolded isoform that stabilize and rendered
unfunctional also the wt quote. This was not unexpected as it
is well known that mutant p53 may exert a dominant negative
effect by preventing wt p53 from binding to the promoter of its
target genes.52
As in SY5Y-APP clone a redox unbalance was evident, we
cannot exclude that NADH quinone oxidoreductase (NQO1),
which is induced in pro-oxidant environment, can contribute to
p53 accumulation in the cell. It is in fact demonstrated that
NQO1 can bind to p53 in a NADH-dependent manner.53
The effects of NQO1 may also explain that in SY5Y-APP cells
wt/unfolded p53 are trapped in the cytoplasm after H2O2 insult
(data not shown).
Apparently these results seem to be in contrast with
numerous studies demonstrating a pro-apoptotic role of p53
upon oxidative stress in neurodegeneration.8,11,54 However,
in a wider context, we can speculate that this ‘no-death’ effect
leads to an accumulation of defective neurons in the SNC and
may contribute to neuronal dysfunction leading to the
development of the disease. Consistent with our findings,
Xu et al.55 demonstrated a loss of p53 pro-apoptotic activity in
cells overexpressing APP695wt. Moreover, Serrano et al.23
demonstrated a significant increase of unfolded p53 in older
AD transgenic mice when compared with younger APPswe/
PS1A246E animals and wild-type counterparts of comparable
age. They also demonstrated that when carcinogen
20-methylcholanthrene compound was injected in tg mice,
they developed brain tumors faster and with higher incidence
than the wild-type counterparts, suggesting impairment in
apoptotic processes. Indeed, ROS may have at least two
distinct roles on p53 functions depending on their insult
degree. Acute oxidative damage induces p53 canonical
pathway, followed by the transactivation of its target genes.
On the other hand, an alteration in oxidative homeostasis,
resulting in a subtoxic and chronic ROS exposure, may affect
p53 tertiary structure and impair its function.56
It is well established that different compounds modulate p53
conformational state.36,41 p53 is endowed with an high
flexibility because of its DNA central domain that contains a
divalent Zn atom coordinated with three cysteines (residues
176, 238, 242) and one histidine (residue 179). Zinc binding is
crucial for the stabilization of p53 protein in folded conforma-
tion.36 Exposure of wild-type p53 to metal chelators results in
a rapid shift towards unfolded p53 isoform; this effect is
accompanied by loss of DNA-binding activity.36,57 Further-
more, Zn treatment at micromolar concentration incorporates
within the protein and restores p53 wild-type PAb1620-
positive conformation.36,41 This effect was also evident in
our experimental procedures, where when we treated SY5Y-
APP cells with zinc chloride, p53 tertiary structure shifted from
unfolded to wild-type conformation. In particular, 24 h 100 mM
ZnCl2, a concentration that did not affect APP levels and
processing (data not shown), reduced the expression of
unfolded p53; notably there is also a decrease of p53wt levels,
after zinc supplementation. This is due to the high turnover of
Figure 7 ZnCl2 restored RA-induced growth cone in SY5Y-APP cells. Cells were treated with 10 mM RA for 48 h. Confocal microscopy was performed with anti-b III tubulin,
anti-GAP-43 antibodies
Figure 8 Schematizion of a proposed molecular cascade
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the protein in native tertiary structure. ZnCl2 pre-treatment
reverted also the resistance to oxidative injury in SY5Y-APP
cells, which resulted more prone to toxic insult. This effect was
p53-dependent, as cell death was prevented by the specific
p53 inhibitor Pif.
Very recently it has been found a new role of p53 protein
that might promote neuronal maturation, as well as axon
outgrowth and regeneration, following neuronal injury.38 In
particular Tedeschi et al.15 demonstrated that acetylation of
lysine residues of p53 promotes neurite outgrowth and
transactivation of GAP-43 gene. In our study, a remarkable
reduction of GAP-43 mRNA and protein levels were found in
SY5Y-APP clone. This observations agree with those studies
in which very low levels of GAP-43 mRNA were found in
cortical neurons of postmortem AD brain in comparison with
control slices, as wells as in APP-transgenic mice.27–29
The decrease of GAP-43 expression in SY5Y-APP cells
was essentially due to the impairment of p53 activity. This was
well demonstrated by ChIP assay, which showed that in basal
conditions p53 was mostly in unfolded conformation and did
not occupy GAP-43 promoter. However, after zinc supple-
mentation, p53 rescued its wild-type conformation and bind
GAP-43 promoter region.
We speculated that the decreased expression of GAP-43 in
SY5Y-APP clone may compromise neuronal plasticity, as the
protein has a key role in regulating axonal growth-cone.17 This
hypothesis was supported essentially by the evidence that only
when SY5Y-APP cells were differentiated by RA in the presence
of zinc chloride (that reverted p53wt state), extensive growth-
cone area, GAP-43 positive, was observed. According with our
observations, Qin et al.,16 showed that treatment of primary
cortical neurons with specific p53 inhibitors or expressing a
p53-R175H-mutant caused growth-cone collapse.
Thus, we propose the following molecular-cascade
(Figure 8): elevated oxidative environment affects p53
conformation towards an unfolded structure. In this unfolded
state, p53 is not able to exert its proapototic activity and
physiological role in axonal outgrowth.
Material and Methods
Cell culture and transfections. Human neuroblastoma cell line SH-SY5Y
was cultured in Ham’s F12 and Dulbecco modified Eagle’s medium in a ratio of
1 : 1, supplemented with 10% (v/v) fetal calf serum, 2 mM glutamine, 50mg/ml
penicillin and 100mg/ml streptomycin and kept at 37 1C in humidified 5% CO2/95%
atmosphere.
SY5Y-APP cells steadily transfected with APP 751 wt were prepared as
follows. SH-SY5Y cells, seeded on polylysine-coated six-well plate at 80% of
confluence density, were transfected with 1 mg/well of pcDNA–APP751 vector using
Lipofectamine 2000 reagent (Invitrogen, Milan, Italy). G418 (Sigma-Aldrich,
St Louis, MO, USA) was added at a concentration of 800mg/ml and drug resistant
cells were collected after 2–3 weeks for single-cell cloning, in 96-well plates. Wells
containing more than one cell were marked and excluded from further investigation.
Fifty percent of the medium in each well was replaced twice a week. After 4–6
weeks, surviving clones reached confluency and were expanded for banking.
Resistant clones were analyzed by western blot to confirm the overexpression of
APP. Steadily transfected cells expressing APP construct were maintained in G418
at a final concentration of 600mg/ml.
H2O2 treatment and evaluation of cell viability. SH-SY5Y empty
vector-transected cells (mock) and SY5Y-APP cells were exposed to H2O2. Briefly,
cells were washed with phosphate buffer saline (PBS) and treated with 1 mM H2O2
for 5 min. After washing, cells were returned to full fresh medium for 24 h.
Cell viability was measured by quantitative colorimetric assay, using 500mg/ml of
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) on cells
incubated at 37 1C for 3 h. MTT was removed and cells were lysed with
dimethyl sulfoxide. The absorbance at 595 nm was measured using a Bio-Rad
3350 microplate reader (Bio Rad Laboratories, Richmond, CA, USA). Control cells
were treated in the same way without H2O2, and the values of different
absorbance were expressed as a percentage of control.
Western blot analysis. Cells were harvested in 80ml of lysis buffer
containing 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 5 mM EDTA, 1 mM phenyl
methyl sulphonyl fluoride, 0.5mg/ml leupeptin, 5 mg/ml aprotinin and 1mg/ml
pepstatin. Protein content was determined by a conventional method (BCA protein
assay kit, Pierce, Rockford, IL, USA). Thirty microgram of protein extracts were
electrophoresed on 12% SDS-PAGE and transferred to nitrocellulose paper
(Schleicher and Schuell, Dassel, Germany). Filters were incubated at 4 1C
overnight with different primary antibodies diluted in 5% non-fat dried milk. For
APP protein and its processing products, the following antibodies were used: an
antibody recognized the N-terminus domain of APP protein (22C11, 1 : 150,
Chemicon Millipore, Billerica, MA, USA), the antibody 6E10, direct towards the
fragment 1–17 of Ab (1 : 200, Sigma-Aldrich), and a C-terminus antibody, against
the nine amino acid from the C-terminus of APP (1 : 250, Sigma-Aldrich). Other
antibodies used: anti-p53 (1 : 1000, Novocastra, Newcastle, UK), anti-p21/WAF1
(1 : 200, Novocastra), anti-GAP-43 (1 : 1500 Chemicon Millipore), and anti-
bIII-tubulin (1 : 2000, Chemicon Millipore), anti-nucleolin (1 : 2000, Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The secondary antibodies (Santa Cruz
Biotechnology) and a chemiluminescence blotting substrate kit (Boehringer,
Mannheim, Germany) were used for immunodetection.
Analysis of p53 conformational state. p53 conformational state was
analyzed by immunopreciptation experiment and ELISA, using the conformational
specific anti-p53 antibodies, PAb1620 and PAb240. In particular, cells were lysed
in immunoprecipitation buffer (10 mM Tris, pH 7.6; 140 mM NaCl; and 0.5% NP40
including protease inhibitors) for 20 min on ice, and cell debris were cleared
by centrifugation. Protein content was determined by a conventional method (BCA
protein assay Kit, Pierce). Before immunoprecipitation experiments, an aliquot of
10mg of protein extracts from each individual sample was processed for western
blot analysis and probed with anti-a tubulin antibody to validate protein content
measurements (data not shown). Based on the previous results, 100mg of protein
extracts were used for immunoprecipitation experiments, performed in a volume of
500ml. To prevent nonspecific binding, the supernatant of immunoprecipitated
samples was precleared with 10% (w/v) protein A/G (50 ml) (SantaCruz
Biotechnology Inc., Heidelberg, Germany) for 20 min on ice, followed by
centrifugation. For immunoprecipitation of p53, 1mg of the conformation-specific
antibodies PAb1620 (wild-type specific) (Calbiochem, EMB Bioscience, La Jolla,
CA, USA) or PAb240 (mutant specific) (Neomarkers-Lab Vision, Fremont,
CA, USA) were added to the samples and incubated overnight at 4 1C.
Immunocomplexes were collected by using protein A/G suspension and washed
five times with immunoprecipitation buffer. Immunoprecipitated p53 was recovered
by resuspending pellets in Laemmli sample buffer. Western blot analysis was
performed using as primary antibodies:polyclonal anti-p53 antibody R19
(SantaCruz Biotechnology Inc.), polyclonal anti-HNE and polyclonal anti-3NT
antibodies. For ELISA assay 70 mg of non-denaturated protein extracts were
diluted in PBS 1 pH 7.4 and coated on the ELISA microplate overnight at 4 1C.
The next day plates were saturated with 100 ml of blocking solution (PBS 1 pH
7.4–0.1% TWEEN 20–3% bovine serum albumin (BSA)) for each well and
incubated for 1 h at room temperature, followed by 2 h incubated at 37 1C with
anti-p53 PAb240 antibody (0.5mg/ml) and Pab1620 (0.5mg/ml). After washing
with PBST (PBS 1 pH 7.4–0.5% TWEEN 20), 0.1 mg/ml secondary anti-mouse
antibody conjugated with peroxidase was incubated in each well for 1 h at room
temperature. Finally, 100ml of TMB (3,3,5,5-tetramethylbenzidine) substrate was
added and the reaction is stopped with 100ml of sulfuric acid 2 M. Optical density
was measured using a microplate reader with a wavelength of 450 nm. Data were
expressed as the mean±S.E. of at least three experiments, performed in
triplicate.
Immunofluorescence and confocal analysis. Cells were plated at a
density of 5 104 cells/cm2 in a 24-well plate, grown on glass coverslip (coated
with poly-D-lysine; Sigma-Aldrich) and then fixed. Cells were incubated in PBS
(Sigma-Aldrich) containing 1% BSA (Sigma-Aldrich) and 0.2% Triton X-100
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overnight at 4 1C with the appropriate antibody. After rinsing, cells were incubated
with the secondary antibody in PBS for 1 h at room temperature. Slices were
mounted using the Dako Fluorescent Mounting Medium and examined by Zeiss
LSM 510 META confocal laser-scanning microscope (Carl Zeiss Inc, Thornwood,
NY, USA). Antibodies used for immunocytochemistry were the following: anti-
GAP-43 (1 : 5000, Chemicon Millipore), anti-bIII tubulin (1 : 200, Chemicon
Millipore), a specific Ab42 polyclonal antibody (1 : 100, Biosource, Carlsbad,
CA, USA). Secondary antibodies used were: anti-mouse CY3 (1 : 500, Invitrogen)
and anti-rabbit Alexa Fluor-conjugated (1 : 500 Invitrogen).
Measurement of oxidative stress markers. Nitro-tyrosine content and
measurement of 4-hydroxynonenal (HNE) were determined immunochemically, as
previously described.58,59 Briefly, samples were incubated in Laemmli sample
buffer in a 1 : 2 ratio (0.125 M Trizma base, pH 6.8, 4% sodium dodecyl sulfate,
20% glycerol) for 20 min. Proteins (5 mg) were then blotted onto the nitrocellulose
paper using the slot-blot apparatus and immunochemical analysis was performed.
The primary anti-3NT antibody (Sigma-Aldrich) diluted 1 : 1000, and anti-HNE
polyclonal antibody (Alpha Diagnostic International Inc., San Antonio, TX, USA)
diluted 1 : 200 were incubated at 4 1C over night, followed by 3 h at room
temperature and then HRP-conjugated goat anti-rabbit antibody (1 : 1500 Dako,
Glostrup, Denmark) at room temperature for 2 h was used for detection. Alfa-
tubulin was used to normalize the sample content. Quantitative analysis was
performed with Scion Image.
Quantitative real-time PCR. One microgram of total RNA from mock and
SY5Y-APP cells was transcribed into cDNA using murine leukemia virus reverse
transcriptase (Promega, Madison, WI, USA) and oligo-dT (15–18) as a primer
(final volume, 50ml). Parallel reactions containing no reverse transcriptase were
used as negative controls to confirm the removal of all genomic DNA. Human-
specific primers were designed using the Primer3 software (http://frodo.wi.mit.edu).60
The oligonucleotide sequences of the primers (M-Medical) used are as follows:
GAP-43, forward primer, 50-TTC TTG GTG TTG TTA TGG CAA G-30, reverse primer,
50-GAG GAA AGT GGA CTC CCA CAG-30; APP, forward primer, 50-AAG AAG
GCA GTT ATC CAG CAT TTC-30, reverse primer, 50-TTG TAG AGC AGG GAG AGA
GAC TGA-30, GAPDH, forward primer, 50-GAG TCA ACG GAT TTG GTC GT-30,
reverse primer, 50-TTG ATT TTG GAG GGA TCT CG-30. Amplification and detection
were performed with the iCYCLER iQ quantitative real-time PCR (Q-RT-PCR)
Detection System (Bio-Rad); the fluorescence signal was generated by SYBR
Green I. Samples were run in triplicate in a 25ml of reaction mix containing 12.5ml of
2 SYBR Green Master Mix (Bio-Rad), 12.5 pmol of each forward and reverse primer
and 2ml of diluted cDNA. Each PCR experiment included serial dilutions of a positive
control for construction of the calibration curve, a positive and a negative DNA sample
and water blanks. The PCR program was initiated by 10 min at 95 1C followed by 40
cycles, each one of 15 s at 95 1C and 1 min at 56–62 1C. A subsequent dissociation
curve analysis verified the Ct for the target gene minus the mean of the Ct for the
internal control gene. The Ct represented the mean difference between the Ct of the
test minus the Ct of the calibrator. The N-fold differential expression in the target gene
of the test compared with calibrator was expressed as 2DDCt. Data analysis and
graphics were performed using GraphPad Prism 4 software (GraphPad, San Diego,
CA, USA) and were the results of at least three different experiments run in triplicate for
each gene.
Transactivation assay. Transient transfections were performed in six multi-
well culture plates, for each well 7 105 cells were seeded in medium without
FBS, antibiotics and with 1% L-glutamine. For transactivation, assay cells were
transfected with the p53-target promoter AIP1-luciferase reporter plasmid (kindly
provided by H Arakawa, National Cancer Center, Tokyo, Japan), by using the
transfection reagent LTX (Invitrogen, Carlsbad, CA, USA) according to the
manufacturer’s instructions. AIP1-luciferase reporter construct plasmid DNA was
co-transfected with pRL-TK Renilla luciferase expressing vector to measure
transfection efficiency (Promega). Eighteen hours later the cells were incubated
with 50mM doxorubicin for 24 h before luciferase activity was assayed. The cells
were then lysed with passive lysis buffer 1 provided by Dual-Luciferase
Reporter Assay System following the manufacturer’s specifications (Promega).
Luminescence was measured employing a 20/20n Luminometer with 10 s of
integration (Turner BioSystems, Sunnyvale, CA, USA). At least six independent
experiments were performed.
Chromatin immunoprecipitation analysis. Chromatin immunoprecipi-
tation (ChIP) analysis was performed as described by Lanni et al.61 Protein
complexes were crosslinked to DNA in living cells by adding formaldehyde directly
to the cell culture medium at 1% final concentration. Chromatin extracts containing
DNA fragments with an average size of 300 bp were incubated overnight at 4 1C
with milk shaking using polyclonal rabbit polyclonal anti-p53 antibody (FL-393,
Santa Cruz), as described by Tedeschi et al.15 DNA–protein complexes were
recovered with protein A/G-agarose (Santa Cruz). Before use, protein A/G was
blocked with 1 mg/ml sheared herring sperm DNA and 1 mg/ml BSA overnight at
4 1C, and then incubated with chromatin and antibodies for 3 h at 4 1C. PCR was
performed using immunoprecipitated DNA and promoter-specific primers flanking
the p53 site for GAP-43 (M-Medical) and specific primers for GAPDH, used as
housekeeping gene. Primer sequences used were as follows: GAP-43 promoter,
forward primer, 50-CCT CTT TAG AAA TAG CTG TTC TTT GC-30, reverse primer,
50-TAA ACA CCT CCA ATC TGG ACC-30; GAPDH, forward primer,
50-GAG TCA ACG GAT TTG GTC GT -30, reverse primer, 50-TTG ATT TTG
GAG GGA TCT CG-30. Immunoprecipitation with nonspecific Igs (no Ab) was
performed as negative controls. PCR products were run on a 2.5% agarose gel
and visualized with ethidium bromide staining using UV light. The amount
of precipitated chromatin measured in each PCR was normalized with the amount
of chromatin present in the input of each immunoprecipitation.
Statistical analysis. Results are given as mean±S.E.M. values. Statistical
significance of differences was determined by mean values of both the t-test
and one-way ANOVA, followed by the Bonferroni test. Significance was accepted
for a Po0.05.
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